Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 7/20 | 0.44 |
| ▸ | BCL2 | P10415 | 2/20 | 0.40 |
| ▸ | BID | P55957 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.40 |
| ▸ | BCL2L10 | Q9HD36 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8514055 | 1.00 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2BCL2BID | |
| SCHEMBL15480782 | 1.00 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2BCL2BID | |
| SCHEMBL8515079 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4ENPC1LMNAHPGD | |
| SCHEMBL15480774 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4ENPC1LMNAHPGD | |
| SCHEMBL15535350 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4ENPC1LMNAHPGD | |
| SCHEMBL15476462 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4ENPC1LMNAHPGD | |
| SCHEMBL15480784 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4ENPC1LMNAHPGD | |
| SCHEMBL15534635 | 0.83 | ALDH1A1 (0.57) | ALDH1A1KDM4ENPC1LMNAHPGD | |
| SCHEMBL15480781 | 0.75 | TAS1R3 (0.50) | TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E | |
| SCHEMBL15480779 | 0.73 | CCR6 (0.41) | BCL2BIDBCL2L1MCL1BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051678-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES | STEMERGIE BIOTECHNOLOGY SA (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140051678-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES | STEMERGIE BIOTECHNOLOGY SA (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2643300-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES | Stemergie Biotechnology SA (CH) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012070015-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES | STEMERGIE BIOTECHNOLOGY SA (CH) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051678-A1 | INHIBITORS OF THE ACTIVITY OF COMPLEX III OF THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN AND USE THEREOF FOR TREATING DISEASES | SQOR, MT-ND3, MT-CO3 | TAS1R3 2477/4885TAS1R1 2959/4885TAS1R2 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.